August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
Japan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesJapan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two Decades
August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
Japan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two DecadesJapan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayEurope Inherits the World’s Aid Bill It Cannot Fully PayAir Passenger Rights Get Their First Overhaul in Two Decades

Medicines Watchdog Backed 104 New Treatments Last Year

Jóhannes Guðnason
Legislative Affairs Editor, Health and Wellbeing

Stockholm: Europe’s medicines regulator had a busy year, and its latest tally shows just how much. The European Medicines Agency recommended 104 new human medicines for approval over the period, including 38 built around a new active substance, many of them aimed at conditions where patients have had few good options. Alongside the human therapies, the agency endorsed 30 new veterinary medicines, underscoring the breadth of a regulator whose decisions ripple across all 27 member states. The figures, set out as the EMA’s management board met in June 2026, are more than a scorecard. Each positive recommendation feeds into a Commission authorisation that opens the entire single market to a new treatment at once, which is why the agency’s throughput matters to companies and patients alike. A high count of novel active substances is a particularly closely watched signal, since these represent genuinely new science rather than reformulations of existing drugs. The board also looked beyond Europe’s borders. Among the topics discussed was deeper collaboration with African regulatory authorities, including support for the response to an Ebola outbreak, a reminder that medicines regulation is increasingly a global enterprise. Diseases do not respect frontiers, and the EMA has been building ties with counterparts abroad to share expertise and speed access to treatments during health emergencies. On the technical side, the agency pressed ahead with modernising its data systems. From 12 June 2026 it released a beta version of a public application programming interface for its product management service, a step toward the structured, machine-readable medicinal data that underpins faster reviews and better pharmacovigilance. It is the kind of unglamorous plumbing that rarely makes headlines but quietly determines how efficiently the system runs. Taken together, the year’s work paints a picture of a regulator under steady pressure to do more. Demand for new therapies keeps rising, the science grows more complex, and the agency is expected to move quickly without compromising safety. The 104 recommendations suggest it is keeping pace, at least for now. The harder question is whether Europe can turn regulatory approval into actual access. A medicine cleared in Amsterdam still has to clear national pricing and reimbursement hurdles before it reaches a patient in Lisbon or Riga, and those delays remain stubbornly long. The EMA can open the door to the single market, but what happens on the other side is largely out of its hands.

Comments